公开(公告)号：US20220119387A1

公开(公告)日：2022-04-21

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. REICH ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11286268B1

公开(公告)日：2022-03-29

申请号：US16916820

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Samuel Sperry ,  Alan X. Xiang ,  Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Mike Shaghafi ,  Theo Michels ,  Christian Nilewski ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan Grubbs ,  Kaveri Urkalan ,  Takasuke Mukaiyama

IPC: C07D519/00 ,  C07D495/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11130757B2

公开(公告)日：2021-09-28

申请号：US16661507

申请日：2019-10-23

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: A61K31/506 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US09814718B2

公开(公告)日：2017-11-14

申请号：US15611966

申请日：2017-06-02

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/52 ,  A61K31/519 ,  C07D487/04 ,  A61K31/551 ,  C07D519/00 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  C07D471/10 ,  C07D473/34

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US09669031B2

公开(公告)日：2017-06-06

申请号：US15187854

申请日：2016-06-21

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: A61K31/506 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00 ,  C07D473/34 ,  C07D487/04 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US09382248B2

公开(公告)日：2016-07-05

申请号：US14748990

申请日：2015-06-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00 ,  C07D473/34 ,  C07D487/04

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Abstract translation: 本发明涉及式（I）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2，R3，R4a，R4b，R5，R6，R7，R8，W1，W2，Y和n 如本文所定义。 还描述了式I化合物的药学上可接受的组合物以及利用式I化合物和式I化合物的药学上可接受的组合物作为Mnk抑制剂以及用于治疗诸如癌症的疾病的治疗剂的方法。

公开(公告)号：US20150376181A1

公开(公告)日：2015-12-31

申请号：US14748990

申请日：2015-06-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: C07D471/04 ,  C07D495/20 ,  C07D519/00 ,  C07D491/20 ,  C07D471/10 ,  C07D471/20

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Abstract translation: 本发明涉及式（I）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2，R3，R4a，R4b，R5，R6，R7，R8，W1，W2，Y和n 如本文所定义。 还描述了式I化合物的药学上可接受的组合物以及利用式I化合物和式I化合物的药学上可接受的组合物作为Mnk抑制剂以及用于治疗诸如癌症的疾病的治疗剂的方法。